Myocardial Infarction Type 2NCT06736353
Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study
An observational study of Myocardial Infarction Type 2, run by Uppsala University at 1 site in Sweden.
Trial summary
A classic heart attack is caused by a blockage to the coronary arteries that supplies the heart muscle with oxygenated blood. The medical term for this condition is type 1 myocardial infarction. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myocardial Infarction Type 2
- How many people
- 14,000 participants
- Where
- 1 siteSweden
- Study dates
- 3 Sep 2010to 5 May 2022
- How long will I take part?
- 6 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients reported as type 2 myocardial infarction (first reporting) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). SWEDEHEART is a Swedish national register for coronary artery disease care and valvular interventions. All Swedish hospitals report to SWEDEHEART. Reported myocardial infarction patients have been classified into type 1-5 since 2010 by the reporting physician. All patients will be included, from the first reporting, until the date of data collection.
Who may be able to join
- Reported as Type 2 MI in SWEDEHEART
- Age >18 years
- Alive at time zero (hospital discharge)
- Reported as Type 2 MI in SWEDEHEART
- Age >18 years
- Alive at time zero (hospital discharge)
Show all 15Show fewer
- Reported as Type 2 MI in SWEDEHEART
- Age >18 years
- Alive at time zero (hospital discharge)
- Reported as Type 2 MI in SWEDEHEART
- Age >18 years
- Alive at time zero (hospital discharge)
- Reported as Type 2 MI in SWEDEHEART
- Age >18 years
- Alive at time zero (hospital discharge)
Who cannot join
- Already on beta blocker
- Heart failure with reduced ejection fraction
- Hypertrophic obstructive cardiomyopathy
- Systolic blood pressure <90 mmHg
- Heart rate <50 bpm
- Metastatic cancer (proxy for terminal disease)
Show all 60Show fewer
- History of dementia or substance abuse last 6 months (proxy for unable to adhere to treatment)
- Missing data for any exclusion criteria
- RAAS blocker target trial emulation:
- Already on RAAS blocker
- Heart failure with reduced ejection fraction
- Combination of prior myocardial infarction and diabetes mellitus
- Diabetic nephropathy,
- Systolic blood pressure <90 mmHg
- Hyperkalemia
- Acute renal failure
- Pregnancy
- Metastatic cancer (proxy for terminal disease)
- History of dementia or substance abuse last 6 months (proxy for unable to adhere to treatment)
- Missing data for any exclusion criteria
- Statin target trial emulation:
- Already on Statin
- Revascularization during hospitalization
- Obstructive coronary artery disease detected during hospitalization
- History of myocardial infarction or coronary revascularization
- History of stroke
- History of peripheral artery disease
- Familial hypercholesterolemia
- Pregnancy
- Acute or chronic liver failure
- Metastatic cancer (proxy for terminal disease)
- History of dementia or substance abuse last 6 months (proxy for unable to adhere to treatment)
- Missing data for any exclusion criteria
- Single Antiplatelet Therapy target trial emulation:
- Already on antiplatelet therapy
- Revascularization during hospitalization
- Obstructive coronary artery disease detected during hospitalization
- Indication for dual antiplatelet therapy according to treating physician
- History of myocardial infarction or coronary revascularization
- History of stroke
- History of peripheral artery disease
- Severe anemia (Hemoglobin <90g/L)
- Intracranial or gastrointestinal bleeding within the last 12 months
- Bleeding disorder
- Acute bleeding during hospitalization
- Metastatic cancer (proxy for terminal disease)
- History of dementia or substance abuse last 6 months (proxy for unable to adhere to treatment)
- Missing data for any exclusion criteria
- Dual Antiplatelet Therapy target trial emulation:
- Already on Dual Antiplatelet Therapy
- Revascularization during hospitalization
- Severe anemia (Hemoglobin <90g/L)
- Pregnancy
- Treatment with oral anticoagulants
- Intracranial or gastrointestinal bleeding within the last 12 months
- Bleeding disorder
- Acute bleeding during hospitalization
- Metastatic cancer (proxy for terminal disease)
- History of dementia or substance abuse last 6 months (proxy for unable to adhere to treatment)
- Missing data for any exclusion criteria
Trial locations and contacts
1 site in 1 country.
Sweden1 site
Department of medical sciences, Uppsala University
Uppsala, 751 05
About this study
A classic heart attack is caused by a blockage to the coronary arteries that supplies the heart muscle with oxygenated blood. The medical term for this condition is type 1 myocardial infarction. There is strong scientific evidence that the usage of pharmacological drugs such as statins, beta blockers, Renin-Angiotensin-Aldosterone System blockers and platelet inhibitors after a type 1 myocardial infarction improves survival and reduces the risk for new myocardial infarctions. However, a myocardial infarction may also occur without blockage to the coronary arteries when other acute conditions causes either a decreased supply or an increased demand of oxygenated blood to the heart. The medical term for the latter is type 2 myocardial infarction. There are currently no scientific evidence that any pharmacological drug improves survival in patients with a type 2 myocardial infarction, of whom only one in three patients are alive after five years.
The aim of this study is to investigate if those drugs that improves the prognosis after a type 1 myocardial infarction (Beta blockers, Renin-Angiotensin-Aldosterone System blockers, Statins and platelet inhibitors) also affects the prognosis after a type 2 myocardial infarction.
Read more
The best way to answer this question would be to conduct clinical trials for each drug where type 2 myocardial infarction patients are randomized to either receiving the drug of interest or receiving placebo (sugar pills) and then compare the survival and outcomes in both groups over time.
However, clinical trials are costly, time consuming and also difficult to conduct with type 2 myocardial infarction patients since these patients are treated at various hospital departments.
Therefore, this study will instead include patients in a Swedish national register for myocardial infarction, in which myocardial infarction patients are reported from all Swedish hospitals, and compare type 2 myocardial infarction patients that did receive or did not receive each treatment. To minimize the risk of making inaccurate conclusions about the causal relationship between treatment and outcome, the study will define the optimal clinical trial for each treatment and then specifically emulate these trials in all possible aspects using the register data. This method is called "target trial emulation".
Read the detailed description
While acute and long term treatments in type 1 myocardial infarction (MI) are well documented, there are no evidence based treatments altering the prognosis in type 2 MI patients, of whom only one in three are alive after five years. Classic secondary preventive treatment in type 1 MI include the use of statins, beta blockers, renin-angiotensin-aldosterone system (RAAS) inhibitors, single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT). While some observational studies suggest classic secondary preventive MI treatment to be associated with better survival in type 2 MI, others do not.
The aim of this study is to investigate if there is an association between treatment with each of statins, beta blockers, RAAS inhibitors, SAPT or DAPT; and all-cause mortality or long-term cardiovascular events in patients with type 2 MI.
The study will be conducted as (several) registry-based observational studies emulating pre-specified target trials. A protocol of a pragmatic randomized controlled trial (a target trial) will be specified for each of statins, beta blockers, RAAS inhibitors, SAPT and DAPT; including eligibility criteria, treatment assignment, time zero and follow up, outcomes, causal contrast and statistical analyses.
Each of these components will then be emulated using registry data. The target trial, as well as the registry-based study emulating the target trial, will differ slightly for each treatment.
The study will include all, approximately 14 000, patients reported as type 2 MI (first reporting for each patient) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) from 2010 and onward. Data from SWEDEHEART will be merged with data from the National Patient Register, the Swedish Cause of Death Register and the Longitudinal Integrated Database for Health Insurance and Labour Market Studies.
Patients will be followed from hospital discharge (time zero) until death, loss to follow-up or end of follow up (date of data collection). Treatment specific eligibility criteria will be applied at time zero. All important confounding factors at time zero will be identified by drawing causal diagrams, one for each treatment and outcome. Treatment specific models with registry data will then be created to balance the assigned groups using for example inverse probability weighting with multiple imputation of missing data among covariates.
For all target trial emulations, the primary outcome of interest will be a composite endpoint of all-cause mortality, readmission for MI, stroke or heart failure. Secondary outcomes will be all-cause mortality, cardiovascular mortality, readmission for MI, readmission for stroke and readmission for heart failure individually. Safety outcomes will be specified separately for each treatment. Readmission for bacterial pneumonia will be used as a negative control outcome in all target trial emulations to check for residual confounding. Intention-to-treat analysis will be performed for each treatment and outcome. Competing risk methodology will be applied as appropriate.
- Conditions
- Myocardial Infarction Type 2
- Being tested
- Beta Blocker Therapy or No Therapy (Control), RAAS blocker Therapy or No therapy (Control), Statin Therapy or No Therapy (Control), Single Antiplatelet Therapy or No Therapy (Control), Dual Antiplatelet Therapy or No Therapy (Control)
- Keywords
- Target trial emulation, Beta blocker, Statin, RAAS blocker, Single antiplatelet therapy, Dual antiplatelet therapy, Type 2 myocardial infarction, SWEDEHEART
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beta Blocker Therapy or No Therapy (Control)Drug
Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction
RAAS blocker Therapy or No therapy (Control)Drug
RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction
Statin Therapy or No Therapy (Control)Drug
Statin therapy or no Statin therapy initiated after type 2 myocardial infarction
Single Antiplatelet Therapy or No Therapy (Control)Drug
Single Antiplatelet Therapy or no antiplatelet therapy initiated after type 2 myocardial infarction
Dual Antiplatelet Therapy or No Therapy (Control)Drug
Dual Antiplatelet Therapy or no Dual Antiplatelet Therapy initiated after type 2 myocardial infarction
| Study group | Role | What they receive |
|---|---|---|
| Type 2 myocardial infarction | All patients reported as type 2 myocardial infarction (first reporting) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) Receives: Drug: Beta Blocker Therapy or No Therapy (Control); Drug: RAAS blocker Therapy or No therapy (Control); Drug: Statin Therapy or No Therapy (Control); Drug: Single Antiplatelet Therapy or No Therapy (Control); Drug: Dual Antiplatelet Therapy or No Therapy (Control) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite
Composite endpoint: All-cause mortality, readmission for MI, stroke or heart failure
Measured: From enrollment (hospital discharge after type 2 MI) until Composite endpoint, Loss to follow-up or End of follow up (date of data collection: 05-May-2022)
Secondary outcomes (5)
All-cause mortality
Death from any cause
Measured: From enrollment (hospital discharge after type 2 MI) until Death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022)
Cardiovascular mortality
Death from cardiovascular disease
Measured: From enrollment (hospital discharge after type 2 MI) until Cardiovascular death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for MI
Readmission for myocardial infarction
Measured: From enrollment (hospital discharge after type 2 MI) until Readmission for MI, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for stroke
Readmission for stroke
Measured: From enrollment (hospital discharge after type 2 MI) until Readmission for Stroke, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for heart failure
Readmission for heart failure
Measured: From enrollment (hospital discharge after type 2 MI) until Readmission for Heart failure, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2024
- Study start3 Sep 2010
- Primary completion5 May 2022
- Study completion5 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial Infarction Type 2Studies of the same condition, open and under way.
- More trials run by Uppsala UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 14,000 participants (actual)
- Target duration
- 6 Years
Sponsor and investigators
- Lead sponsor
- Uppsala University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06736353
- Sponsor's protocol ID
- TYPE2_MI_TARGET_TRIALS
- Other IDs
- KF10-0024
- Status last verified
- Mar 2025
- First submitted
- 11 Dec 2024
- Last updated
- 19 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Due to Swedish laws on personal integrity and health data, as well as the Ethics Committee, we are not allowed to make any data included health variables open to the public even if made anonymous. The data could be shared with other researchers after a request to the head of our department
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study
- ClinicalTrials.gov ID
- NCT06736353
- Acronym / sponsor ID
- TYPE2_MI_TARGET_TRIALS
- Conditions
- Myocardial Infarction Type 2
- Keywords
- Target trial emulation, Beta blocker, Statin, RAAS blocker, Single antiplatelet therapy, Dual antiplatelet therapy, Type 2 myocardial infarction, SWEDEHEART
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 14,000 participants (actual)
- Lead sponsor
- Uppsala UniversityUniversity, hospital or other
- Study start
- 3 Sep 2010 (actual)
- Primary completion
- 5 May 2022 (actual)
- Study completion
- 5 May 2022 (actual)
- First posted
- 16 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A classic heart attack is caused by a blockage to the coronary arteries that supplies the heart muscle with oxygenated blood. The medical term for this condition is type 1 myocardial infarction. There is strong scientific evidence that the usage of pharmacological drugs such as statins, beta blockers, Renin-Angiotensin-Aldosterone System blockers and platelet inhibitors after a type 1 myocardial infarction improves survival and reduces the risk for new myocardial infarctions. However, a myocardial infarction may also occur without blockage to the coronary arteries when other acute conditions causes either a decreased supply or an increased demand of oxygenated blood to the heart. The medical term for the latter is type 2 myocardial infarction. There are currently no scientific evidence that any pharmacological drug improves survival in patients with a type 2 myocardial infarction, of whom only one in three patients are alive after five years.
The aim of this study is to investigate if those drugs that improves the prognosis after a type 1 myocardial infarction (Beta blockers, Renin-Angiotensin-Aldosterone System blockers, Statins and platelet inhibitors) also affects the prognosis after a type 2 myocardial infarction.
The best way to answer this question would be to conduct clinical trials for each drug where type 2 myocardial infarction patients are randomized to either receiving the drug of interest or receiving placebo (sugar pills) and then compare the survival and outcomes in both groups over time.
However, clinical trials are costly, time consuming and also difficult to conduct with type 2 myocardial infarction patients since these patients are treated at various hospital departments.
Therefore, this study will instead include patients in a Swedish national register for myocardial infarction, in which myocardial infarction patients are reported from all Swedish hospitals, and compare type 2 myocardial infarction patients that did receive or did not receive each treatment. To minimize the risk of making inaccurate conclusions about the causal relationship between treatment and outcome, the study will define the optimal clinical trial for each treatment and then specifically emulate these trials in all possible aspects using the register data. This method is called "target trial emulation".
Detailed description
While acute and long term treatments in type 1 myocardial infarction (MI) are well documented, there are no evidence based treatments altering the prognosis in type 2 MI patients, of whom only one in three are alive after five years. Classic secondary preventive treatment in type 1 MI include the use of statins, beta blockers, renin-angiotensin-aldosterone system (RAAS) inhibitors, single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT). While some observational studies suggest classic secondary preventive MI treatment to be associated with better survival in type 2 MI, others do not.
The aim of this study is to investigate if there is an association between treatment with each of statins, beta blockers, RAAS inhibitors, SAPT or DAPT; and all-cause mortality or long-term cardiovascular events in patients with type 2 MI.
The study will be conducted as (several) registry-based observational studies emulating pre-specified target trials. A protocol of a pragmatic randomized controlled trial (a target trial) will be specified for each of statins, beta blockers, RAAS inhibitors, SAPT and DAPT; including eligibility criteria, treatment assignment, time zero and follow up, outcomes, causal contrast and statistical analyses.
Each of these components will then be emulated using registry data. The target trial, as well as the registry-based study emulating the target trial, will differ slightly for each treatment.
The study will include all, approximately 14 000, patients reported as type 2 MI (first reporting for each patient) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) from 2010 and onward. Data from SWEDEHEART will be merged with data from the National Patient Register, the Swedish Cause of Death Register and the Longitudinal Integrated Database for Health Insurance and Labour Market Studies.
Patients will be followed from hospital discharge (time zero) until death, loss to follow-up or end of follow up (date of data collection). Treatment specific eligibility criteria will be applied at time zero. All important confounding factors at time zero will be identified by drawing causal diagrams, one for each treatment and outcome. Treatment specific models with registry data will then be created to balance the assigned groups using for example inverse probability weighting with multiple imputation of missing data among covariates.
For all target trial emulations, the primary outcome of interest will be a composite endpoint of all-cause mortality, readmission for MI, stroke or heart failure. Secondary outcomes will be all-cause mortality, cardiovascular mortality, readmission for MI, readmission for stroke and readmission for heart failure individually. Safety outcomes will be specified separately for each treatment. Readmission for bacterial pneumonia will be used as a negative control outcome in all target trial emulations to check for residual confounding. Intention-to-treat analysis will be performed for each treatment and outcome. Competing risk methodology will be applied as appropriate.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 6 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Type 2 myocardial infarction | – | Drug: Beta Blocker Therapy or No Therapy (Control), Drug: RAAS blocker Therapy or No therapy (Control), Drug: Statin Therapy or No Therapy (Control), Drug: Single Antiplatelet Therapy or No Therapy (Control), Drug: Dual Antiplatelet Therapy or No Therapy (Control)All patients reported as type 2 myocardial infarction (first reporting) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients reported as type 2 myocardial infarction (first reporting) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). SWEDEHEART is a Swedish national register for coronary artery disease care and valvular interventions. All Swedish hospitals report to SWEDEHEART. Reported myocardial infarction patients have been classified into type 1-5 since 2010 by the reporting physician. All patients will be included, from the first reporting, until the date of data collection.
Key inclusion criteria (15 listed)
- Reported as Type 2 MI in SWEDEHEART
- Age >18 years
- Alive at time zero (hospital discharge)
- Reported as Type 2 MI in SWEDEHEART
- Age >18 years
Key exclusion criteria (60 listed)
- Already on beta blocker
- Heart failure with reduced ejection fraction
- Hypertrophic obstructive cardiomyopathy
- Systolic blood pressure <90 mmHg
- Heart rate <50 bpm
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beta Blocker Therapy or No Therapy (Control)Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction | Drug | Type 2 myocardial infarction |
| RAAS blocker Therapy or No therapy (Control)RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction | Drug | Type 2 myocardial infarction |
| Statin Therapy or No Therapy (Control)Statin therapy or no Statin therapy initiated after type 2 myocardial infarction | Drug | Type 2 myocardial infarction |
| Single Antiplatelet Therapy or No Therapy (Control)Single Antiplatelet Therapy or no antiplatelet therapy initiated after type 2 myocardial infarction | Drug | Type 2 myocardial infarction |
| Dual Antiplatelet Therapy or No Therapy (Control)Dual Antiplatelet Therapy or no Dual Antiplatelet Therapy initiated after type 2 myocardial infarction | Drug | Type 2 myocardial infarction |
Primary outcome
Composite
Time frame: From enrollment (hospital discharge after type 2 MI) until Composite endpoint, Loss to follow-up or End of follow up (date of data collection: 05-May-2022)
Composite endpoint: All-cause mortality, readmission for MI, stroke or heart failure
5 secondary outcomes
All-cause mortality
Time frame: From enrollment (hospital discharge after type 2 MI) until Death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022)
Cardiovascular mortality
Time frame: From enrollment (hospital discharge after type 2 MI) until Cardiovascular death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for MI
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for MI, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for stroke
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for Stroke, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for heart failure
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for Heart failure, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2025.
- Individual participant dataSharing planned: Undecided. Due to Swedish laws on personal integrity and health data, as well as the Ethics Committee, we are not allowed to make any data included health variables open to the public even if made anonymous. The data could be shared with other researchers after a request to the head of our department
Related trials for Myocardial Infarction Type 2
Active, not recruitingPhase 3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Recruiting
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
Type 2 Diabetes, Coronary Heart Disease
Active, not recruiting
The Role of 4 Different Consent Approaches on a Pilot Study to Increase Cardiac Rehabilitation Attendance
Ethics, Cardiac Rehabilitation
Recruiting
Enhancing Cardiac Rehabilitation Attendance After Secondary Myocardial Infarction Through Clinician Messaging and Motivational Calls
Type 2 Myocardial Infarction
RecruitingPhase 2
Improving Coronary Vascular Health in Women
HIV-1-infection, Coronary Microvascular Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Infarction Type 2, run by Uppsala University at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 60 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite (time frame: From enrollment (hospital discharge after type 2 MI) until Composite endpoint, Loss to follow-up or End of follow up (date of data collection: 05-May-2022)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2025.